Trial Profile
Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 18 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.